LENZ Therapeutics has unveiled the “Make it VIZZable” campaign to introduce VIZZ™ (aceclidine ophthalmic solution) 1.44% as a once-daily alternative to reading glasses for age-related blurry near vision. Award-winning actor, producer and publisher Sarah Jessica Parker serves as brand ambassador, sharing her personal experience with presbyopia and demonstrating how VIZZ restores near vision clarity for up to ten hours. The campaign features Parker in New York City using the eye drops to read text messages, scan price tags and review scripts without reading glasses. VIZZ is available nationwide by prescription through eye care professionals, with free samples offered at participating practices. In the pivotal Phase 3 CLARITY trial, 93% of participants achieved 20/40 or better near vision within 30 minutes of dosing, with effects lasting up to ten hours, highlighting the product’s rapid onset and durable performance.

LENZ Therapeutics is covered by seven research firms, which collectively assign a consensus recommendation of Moderate Buy. Five analysts have issued buy ratings, one a hold and one a sell. Over the past quarter, key brokerages have reaffirmed positive outlooks, with one increasing its price target and another upgrading to overweight coverage. Recent earnings outperformance—where LENZ reported quarterly revenue of approximately $12.5 million against consensus near $4.6 million—and improving clinical adoption of VIZZ have underpinned analysts’ confidence in LENZ’s commercialization trajectory and its ability to address the estimated 128 million U.S. adults affected by presbyopia.